Adenoviruses in Oncology
- 1 January 2002
- journal article
- Published by Springer Nature in BioDrugs
- Vol. 16 (2) , 77-87
- https://doi.org/10.2165/00063030-200216020-00001
Abstract
The feasibility of using adenoviruses for gene therapy has been under close scrutiny recently, as it has become clear that significant toxicity can result from the strong immune response created by intravenous administration of large doses of first generation adenovirus vectors. This suggests that other vectors could be more useful for treatment of metabolic and hereditary disease, where widespread transduction is often necessary for effective gene replacement, and the viability of target cells is important. However, promising recent results in human cancer trials have confirmed that adenoviruses can be very useful in oncology. For cancer treatment, the unparalleled transduction efficacy of adenovirus in dividing and dormant cells is a major benefit. As the goal in cancer gene therapy is to kill infected tumour cells, long-term transgene expression is not necessary. In addition, the immune response generated against infected cells could be useful for eradicating uninfected tumour. Importantly, more than 670 cancer patients have been treated with adenovirus intratumorally, intra-arterially, intraperitoneally and intravenously with very manageable adverse effects and no unexpected severe or lethal toxicity. Currently, the most promising approaches are based on replication-competent agents that allow efficient tumour penetration because of their capacity for tissue-specific replication. In addition to transcriptional control, it is becoming clear that targeting is necessary for efficient tumour transduction and less infection of normal tissues. Exciting results are anticipated when the first selectively replicating targeted adenoviruses go to clinical trials. In conclusion, intense gene therapy and virological research have suggested that while other vectors could be more useful for treatment of hereditary disease, adenoviruses are highly promising and safe agents for oncology, as suggested in a number of early phase clinical trials.Keywords
This publication has 95 references indexed in Scilit:
- An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene ExpressionMolecular Therapy, 2001
- Does the Antitumor Adenovirus ONYX-015/dl1520 Selectively Target Cells Defective in the p53 Pathway?Journal of Virology, 2001
- E1B-Deleted Adenovirus (dl1520) Gene Therapy for Patients with Primary and Secondary Liver TumorsHuman Gene Therapy, 2001
- Human Gene Marker/Therapy Clinical Protocols (Complete Updated Listings)Human Gene Therapy, 2000
- Efficiency of Adenovirus-Mediated Gene Transfer to Oropharyngeal Epithelial Cells Correlates with Cellular Differentiation and Human Coxsackie and Adenovirus Receptor ExpressionHuman Gene Therapy, 2000
- A Novel, Conditionally Replicative Adenovirus for the Treatment of Breast Cancer That Allows Controlled Replication of E1a-Deleted Adenoviral VectorsHuman Gene Therapy, 2000
- Longitudinal Follow-up of Cellular and Humoral Immunity Induced by Recombinant Adenovirus-Mediated Gene Therapy in Cancer PatientsHuman Gene Therapy, 2000
- A Phase I Study of Adenovirus Mediated Gene Transfer of Interleukin 2 cDNA into Metastatic Breast Cancer or Melanoma. The Toronto Hospital, Toronto, Ontario, CanadaHuman Gene Therapy, 1997
- Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral VectorsHuman Gene Therapy, 1996
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977